701 related articles for article (PubMed ID: 11981600)
1. High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans.
Donny EC; Walsh SL; Bigelow GE; Eissenberg T; Stitzer ML
Psychopharmacology (Berl); 2002 May; 161(2):202-12. PubMed ID: 11981600
[TBL] [Abstract][Full Text] [Related]
2. Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers.
Donny EC; Brasser SM; Bigelow GE; Stitzer ML; Walsh SL
Addiction; 2005 Oct; 100(10):1496-509. PubMed ID: 16185211
[TBL] [Abstract][Full Text] [Related]
3. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
Correia CJ; Walsh SL; Bigelow GE; Strain EC
Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
[TBL] [Abstract][Full Text] [Related]
4. Influence of the dose on the severity of opiate withdrawal symptoms during methadone detoxification.
Glasper A; Gossop M; de Wet C; Reed L; Bearn J
Pharmacology; 2008; 81(2):92-6. PubMed ID: 17952010
[TBL] [Abstract][Full Text] [Related]
5. Relative potency of levo-alpha-acetylmethadol and methadone in humans under acute dosing conditions.
Eissenberg T; Stitzer ML; Bigelow GE; Buchhalter AR; Walsh SL
J Pharmacol Exp Ther; 1999 May; 289(2):936-45. PubMed ID: 10215673
[TBL] [Abstract][Full Text] [Related]
6. Dose-response analysis of opioid cross-tolerance and withdrawal suppression during LAAM maintenance.
Houtsmuller EJ; Walsh SL; Schuh KJ; Johnson RE; Stitzer ML; Bigelow GE
J Pharmacol Exp Ther; 1998 May; 285(2):387-96. PubMed ID: 9580575
[TBL] [Abstract][Full Text] [Related]
7. l-alpha-Acetylmethadol, l-alpha-acetyl-N-normethadol and l-alpha-acetyl-N,N-dinormethadol: comparisons with morphine and methadone in suppression of the opioid withdrawal syndrome in the dog.
Vaupel DB; Jasinski DR
J Pharmacol Exp Ther; 1997 Nov; 283(2):833-42. PubMed ID: 9353405
[TBL] [Abstract][Full Text] [Related]
8. Choice between heroin and food in nondependent and heroin-dependent rhesus monkeys: effects of naloxone, buprenorphine, and methadone.
Negus SS
J Pharmacol Exp Ther; 2006 May; 317(2):711-23. PubMed ID: 16456085
[TBL] [Abstract][Full Text] [Related]
9. Tramadol versus methadone for treatment of opiate withdrawal: a double-blind, randomized, clinical trial.
Zarghami M; Masoum B; Shiran MR
J Addict Dis; 2012; 31(2):112-7. PubMed ID: 22540433
[TBL] [Abstract][Full Text] [Related]
10. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.
Strain EC; Preston KL; Liebson IA; Bigelow GE
J Pharmacol Exp Ther; 1995 Feb; 272(2):628-38. PubMed ID: 7853176
[TBL] [Abstract][Full Text] [Related]
11. Acetyl-L-carnitine in the management of pain during methadone withdrawal syndrome.
Janiri L; Martinotti G; Tonioni F; Ghelardini C; Nicolai R; Galeotti N; Mosconi L; Calvani M; Bartolini A; Iannoni E
Clin Neuropharmacol; 2009; 32(1):35-40. PubMed ID: 18978503
[TBL] [Abstract][Full Text] [Related]
12. Effects of a single 50% extra dose of methadone on heroin craving and mood in lower- versus higher-dose methadone patients.
Strasser J; Wiesbeck GA; Meier N; Stohler R; Dürsteler-Macfarland KM
J Clin Psychopharmacol; 2010 Aug; 30(4):450-4. PubMed ID: 20571436
[TBL] [Abstract][Full Text] [Related]
13. Exploring the relationship between perceived inter-dose opioid withdrawal and patient characteristics in methadone maintenance treatment.
Elkader AK; Brands B; Callaghan R; Sproule BA
Drug Alcohol Depend; 2009 Dec; 105(3):209-14. PubMed ID: 19713051
[TBL] [Abstract][Full Text] [Related]
14. When "enough" is not enough: new perspectives on optimal methadone maintenance dose.
Leavitt SB; Shinderman M; Maxwell S; Eap CB; Paris P
Mt Sinai J Med; 2000; 67(5-6):404-11. PubMed ID: 11064491
[TBL] [Abstract][Full Text] [Related]
15. Effects of methadone or buprenorphine maintenance on the subjective and reinforcing effects of intravenous cocaine in humans.
Foltin RW; Fischman MW
J Pharmacol Exp Ther; 1996 Sep; 278(3):1153-64. PubMed ID: 8819498
[TBL] [Abstract][Full Text] [Related]
16. Slow-release oral morphine for maintenance treatment of opioid addicts intolerant to methadone or with inadequate withdrawal suppression.
Kastelic A; Dubajic G; Strbad E
Addiction; 2008 Nov; 103(11):1837-46. PubMed ID: 19032534
[TBL] [Abstract][Full Text] [Related]
17. Antinociceptive effects of high-dose remifentanil in male methadone-maintained patients.
Hay JL; White JM; Bochner F; Somogyi AA
Eur J Pain; 2008 Oct; 12(7):926-33. PubMed ID: 18262451
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of an injection depot formulation of buprenorphine: placebo comparison.
Sigmon SC; Wong CJ; Chausmer AL; Liebson IA; Bigelow GE
Addiction; 2004 Nov; 99(11):1439-49. PubMed ID: 15500597
[TBL] [Abstract][Full Text] [Related]
19. Comparison of buprenorphine and methadone in the treatment of opiate withdrawal: possible advantages of buprenorphine for the treatment of opiate-benzodiazepine codependent patients?
Reed LJ; Glasper A; de Wet CJ; Bearn J; Gossop M
J Clin Psychopharmacol; 2007 Apr; 27(2):188-92. PubMed ID: 17414244
[TBL] [Abstract][Full Text] [Related]
20. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine.
Strain EC; Walsh SL; Bigelow GE
Psychopharmacology (Berl); 2002 Jan; 159(2):161-6. PubMed ID: 11862344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
